GlaxoSmithKline News and Research

RSS

Genmab reaches milestones in Ofatumumab collaboration

The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007.

22 Jan 2008

Selective publication means unfavorable drug studies rarely get published

A new report claims that almost a third of the research done on antidepressant drugs is never published in medical literature and most of those unpublished reports are unfavorable.

20 Jan 2008

Drug effective for hepatitis C patients with low platelets

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease.

2 Jan 2008

Combo therapy reduces size of brain tumours

According to a major drug manufacturer, a combination drug treatment appears to be effective in fighting breast cancer that has spread to the brain.

19 Dec 2007

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

17 Dec 2007

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

The following is GlaxoSmithKline's response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

13 Dec 2007

Popular diabetes drug Avandia linked to osteoporosis

New drug, eltrombopag boosts platelets in hepatitis C patients

It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus (HCV) have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of the major reasons why patients can't endure antiviral treatments.

29 Nov 2007

Researchers transfer immune response to myeloma patient

Researchers at the University of Arkansas for Medical Sciences (UAMS) have for the first time transferred an immune response in a healthy individual to a patient with multiple myeloma, a cancer of the bone marrow, showing promise for cancer vaccination.

27 Nov 2007

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

27 Nov 2007

Brits gear up for pandemic while FDA warns about flu jabs side-effects

The British government says it plans to double its stockpile of antiviral drugs such as Tamiflu to cope with the possibility of a flu pandemic.

26 Nov 2007

GlaxoSmithKline to acquire Reliant Pharmaceuticals

GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.

21 Nov 2007

Early warning for anti-smoking drug Chantix

The drug watchdog in the United States, the Food and Drug Administration (FDA), has expressed concerns regarding the anti-smoking drug Chantix.

21 Nov 2007

Funds to boost UK methods research

A new programme to strengthen the UK's position as a leader in the methods that underpin health research has been announced by the Medical Research Council and the National Institute for Health Research.

19 Nov 2007

Rev-erb protein helps maintain the body's correct metabolism

It's well known that the body's energy levels cycle on a 24-hour, or circadian, schedule, and that this metabolic process is fueled by oxygen.

19 Nov 2007

Top selling diabetes drug to carry back box warning

The government watchdog body in the U.S., The Food and Drug Administration (FDA), has placed a "black box" warning on the popular drug Avandia.

15 Nov 2007

GlaxoSmithKline implements changes to the US product label for Avandia

GlaxoSmithKline announced today that it is implementing changes to the US product label for Avandia(R) (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti-diabetic medicine available.

15 Nov 2007

FDA adds warning for heart attacks to type 2 diabetes drug Avandia

The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.

14 Nov 2007

Fabre Kramer Pharmaceuticals receives FDA decision on Gepirone ER for major depressive disorder

Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.

5 Nov 2007

Potent inhibitor of Kinesin CENP-E demonstrates tumor cell inhibition

A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers from GlaxoSmithKline.

24 Oct 2007